S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
OTCMKTS:TRSBF

3SBio Stock Forecast, Price & News

$0.80
0.00 (0.00 %)
(As of 10/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.80
$0.80
50-Day Range
$0.80
$0.80
52-Week Range
$0.80
$1.00
VolumeN/A
Average Volume63,275 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TRSBF News and Ratings via Email

Sign-up to receive the latest news and ratings for 3SBio and its competitors with MarketBeat's FREE daily newsletter.


About 3SBio

3SBio Inc. researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and INV. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:TRSBF
CIK
N/A
Employees
5,522
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












3SBio (OTCMKTS:TRSBF) Frequently Asked Questions

Is 3SBio a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 3SBio in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" 3SBio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TRSBF, but not buy additional shares or sell existing shares.
View analyst ratings for 3SBio
or view top-rated stocks.

What stocks does MarketBeat like better than 3SBio?

Wall Street analysts have given 3SBio a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but 3SBio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are 3SBio's key executives?

3SBio's management team includes the following people:
  • Dr. Jing Lou, Co-Founder, Exec. Chairman, CEO & Pres (Age 58, Pay $577.76k)
  • Dr. Dongmei Su, Sr. VP & Exec. Director (Age 51, Pay $216.04k)
  • Mr. Fei Wang, Chief Financial Officer (Age 43)
  • Mr. Weihong Xiao, Chief Operating Officer (Age 52)
  • Ms. Lu Xia, Director of Investor Relations (Age 36)
  • Ms. Hui Dang, Director of Risk and Compliance Management (Age 49)
  • Mr. Thomas Folinsbee C.F.A., CFA, Director of Corp. Devel. (Age 53)
  • Mr. Xin Ma, VP of the HR Department (Age 60)
  • Ms. Fei You, Director of the Fin. Department & Financial Controller (Age 42)
  • Mr. Junlin Wang, Pres of Guojian (Age 48)

What is 3SBio's stock symbol?

3SBio trades on the OTCMKTS under the ticker symbol "TRSBF."

How do I buy shares of 3SBio?

Shares of TRSBF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 3SBio's stock price today?

One share of TRSBF stock can currently be purchased for approximately $0.80.

How many employees does 3SBio have?

3SBio employs 5,522 workers across the globe.

What is 3SBio's official website?

The official website for 3SBio is www.3sbio.com.

Where are 3SBio's headquarters?

How can I contact 3SBio?

3SBio's mailing address is Shenyang Economy & Tech Development, Shenyang, Liaoning 110027. The company can be reached via phone at 86 24 2538 6000.


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.